

SUPPLEMENT 3. Summary of Baseline Ribotypes<sup>†</sup>

	Bezlotoxumab		Placebo		Total	
	n	(%)	n	(%)	n	(%)
Participants in population	104		35		139	
Participants with ribotype assessment	55	(52.9)	20	(57.1)	75	(54.0)
<b>Summary of Ribotype by descending order</b>						
014	8	(7.7)	4	(11.4)	12	(8.6)
106	7	(6.7)	3	(8.6)	10	(7.2)
017	3	(2.9)	1	(2.9)	4	(2.9)
023	4	(3.8)	0	(0.0)	4	(2.9)
027	3	(2.9)	1	(2.9)	4	(2.9)
002	1	(1.0)	1	(2.9)	2	(1.4)
005	2	(1.9)	0	(0.0)	2	(1.4)
012	2	(1.9)	0	(0.0)	2	(1.4)
020	0	(0.0)	2	(5.7)	2	(1.4)
046	2	(1.9)	0	(0.0)	2	(1.4)
057	2	(1.9)	0	(0.0)	2	(1.4)
103	2	(1.9)	0	(0.0)	2	(1.4)
126	2	(1.9)	0	(0.0)	2	(1.4)
220	2	(1.9)	0	(0.0)	2	(1.4)
255	2	(1.9)	0	(0.0)	2	(1.4)
001	1	(1.0)	0	(0.0)	1	(0.7)
018	0	(0.0)	1	(2.9)	1	(0.7)
026	1	(1.0)	0	(0.0)	1	(0.7)
043	0	(0.0)	1	(2.9)	1	(0.7)
045	0	(0.0)	1	(2.9)	1	(0.7)
054	1	(1.0)	0	(0.0)	1	(0.7)
056	1	(1.0)	0	(0.0)	1	(0.7)
070	0	(0.0)	1	(2.9)	1	(0.7)
076	1	(1.0)	0	(0.0)	1	(0.7)
078	0	(0.0)	1	(2.9)	1	(0.7)
097	1	(1.0)	0	(0.0)	1	(0.7)
111	0	(0.0)	1	(2.9)	1	(0.7)
153	1	(1.0)	0	(0.0)	1	(0.7)
154	1	(1.0)	0	(0.0)	1	(0.7)
216	0	(0.0)	1	(2.9)	1	(0.7)
228	1	(1.0)	0	(0.0)	1	(0.7)
244	1	(1.0)	0	(0.0)	1	(0.7)
287	1	(1.0)	0	(0.0)	1	(0.7)
600	1	(1.0)	0	(0.0)	1	(0.7)
987	1	(1.0)	0	(0.0)	1	(0.7)
1001	0	(0.0)	1	(2.9)	1	(0.7)
<b>027 Ribotype</b>						
Yes	3	(2.9)	1	(2.9)	4	(2.9)
No	52	(50.0)	19	(54.3)	71	(51.1)
<b>Hypervirulent strain (027, 078, or 244 ribotypes)</b>						
Yes	4	(3.8)	2	(5.7)	6	(4.3)
No	51	(49.0)	18	(51.4)	69	(49.6)
† As determined by polymerase chain reaction. Percentages are based on all participants in the population.						